NeoGenomics Reports Strong Q1 Revenue Growth, Reduced Net Loss, and Improved Operating Cash Flow

summarizeSummary

NeoGenomics reported an 11.1% increase in Q1 revenue, significantly reduced its net loss, and improved operating cash flow, while affirming sufficient liquidity for the next 12 months.

check_boxKey Events

• Strong Q1 Revenue Growth

  Net revenue increased 11.1% to $186.7 million for the three months ended March 31, 2026, compared to $168.0 million in the prior year period.

• Reduced Net Loss

  The company significantly narrowed its net loss to $17.1 million in Q1 2026, an improvement from a net loss of $25.9 million in Q1 2025.

• Improved Operating Cash Flow

  Cash used in operating activities decreased substantially to $8.1 million in Q1 2026, compared to $25.3 million used in Q1 2025.

• Positive Liquidity Outlook

  Management stated that cash on hand of $146.1 million as of March 31, 2026, and cash collections are sufficient to fund operating needs for at least the next 12 months.

auto_awesomeAnalysis

NeoGenomics reported a strong first quarter, with net revenue increasing by 11.1% to $186.7 million, aligning with previously reported figures that surpassed analyst estimates. The company significantly reduced its net loss to $17.1 million from $25.9 million in the prior year, and notably improved its operating cash flow, reducing cash used in operations from $25.3 million to $8.1 million. Management also affirmed that current cash and cash collections are sufficient to fund operations for at least the next 12 months, providing a positive outlook on liquidity. While the company continues to navigate an ongoing regulatory investigation with an existing $11.2 million reserve and an appealed shareholder class action lawsuit, these are not new material developments in this report. Additionally, the Board Chair adopted a routine 10b5-1 trading plan for a modest number of shares.